Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLAD of intrathecal bupivacaine in anterior supine intermuscular total hip arthroplasty
NL-OMON43572Phase 4Active, not recruiting
- Sponsor
- Reinier de Graaf Hospital
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bupivacaine in Not applicable, sponsored by Reinier de Graaf Hospital. Primary endpoint: Median local anesthetic dose (MLAD/ED50) of bupivacaine at 119 minutes. Started Oct 2015; status: active, not recruiting.
02
Drugs
bupivacaine
03
Conditions
Not applicable
Beyond the preview
Go deeper on NL-OMON43572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43572.